|
US7094770B2
(en)
|
2000-04-13 |
2006-08-22 |
Pharmasset, Ltd. |
3′-or 2′-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
|
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
|
CZ301182B6
(en)
|
2000-05-26 |
2009-12-02 |
Idenix (Cayman) Limited |
Use of nucleoside derivatives for preparation of pharmaceutical compositions for treating infections caused by flaviviruses and pestiviruses
|
|
WO2003026589A2
(en)
|
2001-09-28 |
2003-04-03 |
Idenix (Cayman) Limited |
Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
|
|
WO2004002422A2
(en)
|
2002-06-28 |
2004-01-08 |
Idenix (Cayman) Limited |
2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
|
CN101172993A
(en)
|
2002-06-28 |
2008-05-07 |
埃迪尼克斯(开曼)有限公司 |
2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
|
AU2003256619A1
(en)
|
2002-07-24 |
2004-02-09 |
Isis Pharmaceuticals, Inc. |
Pyrrolopyrimidine thionucleoside analogs as antivirals
|
|
IL166640A0
(en)
|
2002-08-01 |
2006-01-15 |
Pharmasset Ltd |
Compounds with the bicyclo Ä4.2.1Ü nonane system for the treatment of flaviviridae infections
|
|
EA200500584A1
(en)
*
|
2002-09-30 |
2006-02-24 |
Дженелэбс Текнолоджиз, Инк. |
NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF INFECTIOUS DISEASES CAUSED BY THE HEPATITIS C VIRUS
|
|
US7094768B2
(en)
|
2002-09-30 |
2006-08-22 |
Genelabs Technologies, Inc. |
Nucleoside derivatives for treating hepatitis C virus infection
|
|
ES2624353T3
(en)
|
2002-11-15 |
2017-07-13 |
Idenix Pharmaceuticals Llc |
2'-Methyl nucleosides in combination with interferon and Flaviviridae mutation
|
|
RU2005121904A
(en)
|
2002-12-12 |
2006-01-20 |
Айденикс (Кайман) Лимитед (Ky) |
METHOD FOR PRODUCING 2`-BRANCHED NUCLEOSIDES
|
|
WO2004065398A2
(en)
*
|
2003-01-15 |
2004-08-05 |
Ribapharm Inc. |
Synthesis and use of 2'-substituted-n6-modified nucleosides
|
|
EP4032897B1
(en)
|
2003-05-30 |
2025-01-29 |
Gilead Pharmasset LLC |
Modified fluorinated nucleoside analogues
|
|
ATE478886T1
(en)
*
|
2003-07-25 |
2010-09-15 |
Idenix Pharmaceuticals Inc |
PURINE NUCLEOSIDES FOR THE TREATMENT OF DISEASES CAUSED BY FLAVIVIDRAE, INCLUDING HEPATITIS C
|
|
US7151089B2
(en)
|
2003-10-27 |
2006-12-19 |
Genelabs Technologies, Inc. |
Nucleoside compounds for treating viral infections
|
|
EP1687321A1
(en)
*
|
2003-10-27 |
2006-08-09 |
Genelabs Technologies, Inc. |
Nucleoside compounds for treating viral infections
|
|
US7202223B2
(en)
|
2003-10-27 |
2007-04-10 |
Genelabs Technologies, Inc. |
Nucleoside compounds for treating viral infections
|
|
US7157434B2
(en)
*
|
2003-10-27 |
2007-01-02 |
Genelabs Technologies, Inc. |
Nucleoside compounds for treating viral infections
|
|
WO2005044835A1
(en)
*
|
2003-10-27 |
2005-05-19 |
Genelabs Technologies, Inc. |
METHODS FOR PREPARING 7-(2'-SUBSTITUTED-ß-D-RIBOFURANOSYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES
|
|
US20050182252A1
(en)
|
2004-02-13 |
2005-08-18 |
Reddy K. R. |
Novel 2'-C-methyl nucleoside derivatives
|
|
IN2012DN04853A
(en)
|
2004-02-20 |
2015-09-25 |
Boehringer Ingelheim Int |
|
|
AR049384A1
(en)
|
2004-05-24 |
2006-07-26 |
Glaxo Group Ltd |
PURINA DERIVATIVES
|
|
CN101023094B
(en)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
|
|
WO2006031725A2
(en)
|
2004-09-14 |
2006-03-23 |
Pharmasset, Inc. |
Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
|
|
US7414031B2
(en)
|
2004-11-22 |
2008-08-19 |
Genelabs Technologies, Inc. |
5-nitro-nucleoside compounds for treating viral infections
|
|
US7524831B2
(en)
|
2005-03-02 |
2009-04-28 |
Schering Corporation |
Treatments for Flaviviridae virus infection
|
|
WO2007084157A2
(en)
*
|
2005-03-23 |
2007-07-26 |
Genelabs Technologies, Inc. |
Nucleoside prodrugs for treating viral infections
|
|
GB0514809D0
(en)
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
|
US20090118220A1
(en)
*
|
2006-04-03 |
2009-05-07 |
Astrazeneca Ab |
Substituted adenines and the uses thereof
|
|
WO2008005542A2
(en)
*
|
2006-07-07 |
2008-01-10 |
Gilead Sciences, Inc., |
Antiviral phosphinate compounds
|
|
GB0623493D0
(en)
|
2006-11-24 |
2007-01-03 |
Univ Cardiff |
Chemical compounds
|
|
US7951789B2
(en)
|
2006-12-28 |
2011-05-31 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
EP2028182A1
(en)
*
|
2007-08-21 |
2009-02-25 |
Glaxo Group Limited |
Cysteine protease inhibitors
|
|
WO2008117046A1
(en)
*
|
2007-03-27 |
2008-10-02 |
Astrazeneca Ab |
Pyrazolo [4, 3-d] pyrimidines as antibacterial compounds
|
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
|
US8227431B2
(en)
|
2008-03-17 |
2012-07-24 |
Hetero Drugs Limited |
Nucleoside derivatives
|
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
|
EP2313102A2
(en)
|
2008-07-03 |
2011-04-27 |
Biota Scientific Management |
Bycyclic nucleosides and nucleotides as therapeutic agents
|
|
WO2010027935A1
(en)
|
2008-09-08 |
2010-03-11 |
Merck Sharp & Dohme Corp. |
Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia
|
|
NZ593647A
(en)
|
2008-12-23 |
2013-08-30 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
|
SG172359A1
(en)
|
2008-12-23 |
2011-07-28 |
Pharmasset Inc |
Nucleoside phosphoramidates
|
|
US8551973B2
(en)
|
2008-12-23 |
2013-10-08 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
|
TWI598358B
(en)
|
2009-05-20 |
2017-09-11 |
基利法瑪席特有限責任公司 |
Nucleoside phosphoramidates
|
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
|
JP2013527145A
(en)
|
2010-03-31 |
2013-06-27 |
ギリード・ファーマセット・エルエルシー |
Stereoselective synthesis of phosphorus-containing activators
|
|
EP2552203B1
(en)
|
2010-04-01 |
2017-03-22 |
Idenix Pharmaceuticals LLC. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
TW201305185A
(en)
*
|
2010-09-13 |
2013-02-01 |
Gilead Sciences Inc |
2'-fluoro substituted carbon-nucleoside analog for antiviral therapy
|
|
CA2810928A1
(en)
|
2010-09-22 |
2012-03-29 |
Alios Biopharma, Inc. |
Substituted nucleotide analogs
|
|
PT3042910T
(en)
|
2010-11-30 |
2019-04-16 |
Gilead Pharmasset Llc |
2'-spiro-nucleosides for use in the therapy of hepatitis c
|
|
US9243025B2
(en)
|
2011-03-31 |
2016-01-26 |
Idenix Pharmaceuticals, Llc |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
CA2840242C
(en)
|
2011-09-16 |
2019-03-26 |
Gilead Sciences, Inc. |
Methods for treating hcv
|
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
|
CA2860234A1
(en)
|
2011-12-22 |
2013-06-27 |
Alios Biopharma, Inc. |
Substituted phosphorothioate nucleotide analogs
|
|
AU2012358803C1
(en)
|
2011-12-22 |
2019-12-19 |
Janssen Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
|
WO2013138236A1
(en)
|
2012-03-13 |
2013-09-19 |
Gilead Sciences , Inc. |
2'- substituted carba-nucleoside analogs for antiviral treatment
|
|
HK1206362A1
(en)
|
2012-03-21 |
2016-01-08 |
Alios Biopharma, Inc. |
Solid form of thiophosphoramidate nucleotide prodrug
|
|
USRE48171E1
(en)
|
2012-03-21 |
2020-08-25 |
Janssen Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
|
US9441007B2
(en)
|
2012-03-21 |
2016-09-13 |
Alios Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
|
US9012427B2
(en)
|
2012-03-22 |
2015-04-21 |
Alios Biopharma, Inc. |
Pharmaceutical combinations comprising a thionucleotide analog
|
|
EP2890704B1
(en)
|
2012-08-31 |
2018-02-28 |
Novartis AG |
2'-ethynyl nucleoside derivatives for treatment of viral infections
|
|
KR20200060782A
(en)
|
2013-01-31 |
2020-06-01 |
길리애드 파마셋 엘엘씨 |
Combination formulation of two antiviral compounds
|
|
CN105705511A
(en)
|
2013-04-12 |
2016-06-22 |
艾其林医药公司 |
Deuterated nucleoside prodrugs useful for treating HCV
|
|
EP3650014B1
(en)
|
2013-08-27 |
2021-10-06 |
Gilead Pharmasset LLC |
Combination formulation of two antiviral compounds
|
|
EP3055319A4
(en)
|
2013-10-11 |
2018-01-10 |
Alios Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
|
WO2015143712A1
(en)
|
2014-03-28 |
2015-10-01 |
Merck Sharp & Dohme Corp. |
4'-substituted nucleoside reverse transcriptase inhibitors
|
|
MY190867A
(en)
|
2015-03-06 |
2022-05-13 |
Atea Pharmaceuticals Inc |
? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
|
|
BR112018002399A2
(en)
|
2015-08-06 |
2018-09-25 |
Chimerix, Inc. |
pyrrolopyrimidine nucleosides and analogs thereof, useful as antiviral agents
|
|
WO2017053216A2
(en)
|
2015-09-23 |
2017-03-30 |
Merck Sharp & Dohme Corp. |
4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
|
|
US10202412B2
(en)
|
2016-07-08 |
2019-02-12 |
Atea Pharmaceuticals, Inc. |
β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
|
|
PL3512863T3
(en)
|
2016-09-07 |
2022-04-04 |
Atea Pharmaceuticals, Inc. |
2'-substituted-n6-substituted purine nucleotides for rna virus treatment
|
|
IL295609B2
(en)
|
2017-02-01 |
2023-11-01 |
Atea Pharmaceuticals Inc |
Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
|
|
EP3684771B1
(en)
|
2017-09-21 |
2024-11-27 |
Chimerix, Inc. |
Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7h-pyrrolo(2,3-d)pyrimidine-5-carboxamide and uses thereof
|
|
US11040975B2
(en)
|
2017-12-08 |
2021-06-22 |
Merck Sharp & Dohme Corp. |
Carbocyclic nucleoside reverse transcriptase inhibitors
|
|
CN112351799A
(en)
|
2018-04-10 |
2021-02-09 |
阿堤亚制药公司 |
Treatment of HCV infected patients with cirrhosis
|
|
US10874687B1
(en)
|
2020-02-27 |
2020-12-29 |
Atea Pharmaceuticals, Inc. |
Highly active compounds against COVID-19
|
|
BR112023026356A2
(en)
|
2021-06-17 |
2024-03-05 |
Atea Pharmaceuticals Inc |
METHOD FOR TREATING HEPATITIS C VIRUS OR A CONDITION RESULTING FROM A HEPATITIS C INFECTION, COMBINATION, USE OF THE COMBINATION, PHARMACEUTICAL COMPOSITION, AND, KIT FOR TREATMENT OF HEPATITIS C VIRUS
|
|
CZ2024224A3
(en)
|
2024-05-30 |
2025-12-10 |
Ústav organické chemie a biochemie AV ČR, v. v. i. |
1H-pyrazolo[3,4-d]pyrimidine ribonucleosides with anti-tumour activity for the therapeutic use
|